HomeCompareACER vs BTI

ACER vs BTI: Dividend Comparison 2026

ACER yields 302.98% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACER wins by $1618.30M in total portfolio value
10 years
ACER
ACER
● Live price
302.98%
Share price
$0.66
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1618.34M
Annual income
$981,251,733.53
Full ACER calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — ACER vs BTI

📍 ACER pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACERBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACER + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACER pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACER
Annual income on $10K today (after 15% tax)
$25,753.67/yr
After 10yr DRIP, annual income (after tax)
$834,063,973.50/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, ACER beats the other by $834,061,591.55/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACER + BTI for your $10,000?

ACER: 50%BTI: 50%
100% BTI50/50100% ACER
Portfolio after 10yr
$809.19M
Annual income
$490,627,267.91/yr
Blended yield
60.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

ACER
Analyst Ratings
1
Strong
3
Buy
4
Hold
Consensus: Hold
Altman Z
-29.9
Piotroski
4/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACER buys
0
BTI buys
0
No recent congressional trades found for ACER or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACERBTI
Forward yield302.98%5.40%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$1618.34M$37.8K
Annual income after 10y$981,251,733.53$2,802.29
Total dividends collected$1554.65M$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy

Year-by-year: ACER vs BTI ($10,000, DRIP)

YearACER PortfolioACER Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$40,998$30,298.44$11,301$601.08+$29.7KACER
2$159,961$116,092.41$12,799$706.58+$147.2KACER
3$594,475$423,317.38$14,527$832.38+$579.9KACER
4$2,106,378$1,470,289.30$16,527$982.75+$2.09MACER
5$7,122,619$4,868,794.58$18,846$1,162.95+$7.10MACER
6$23,007,746$15,386,544.17$21,545$1,379.49+$22.99MACER
7$71,068,926$46,450,637.66$24,694$1,640.41+$71.04MACER
8$210,139,057$134,095,305.48$28,378$1,955.69+$210.11MACER
9$595,407,325$370,558,534.30$32,702$2,337.79+$595.37MACER
10$1,618,337,571$981,251,733.53$37,794$2,802.29+$1618.30MACER

ACER vs BTI: Complete Analysis 2026

ACERStock

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Full ACER Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ACER vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACER vs SCHDACER vs JEPIACER vs OACER vs KOACER vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.